Finding the Optimum Regimen for Duchenne Muscular Dystrophy

PHASE3CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Prednisone

daily prednisone (0.75 mg/kg/day) tablets for 36-60 months

DRUG

Prednisone

intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months

DRUG

Deflazacort

daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months

Trial Locations (32)

10126

Neuromuscular Center University of Turin, Torino

14642

University of Rochester Medical Center, Rochester

17033

Penn State Hershey Medical Center, Hershey

20010

Children's National Medical Center, Washington D.C.

20133

C. Besta Neurological Institute Foundation, Milan

27599

University of North Carolina at Chapel Hill, Chapel Hill

32827

Nemours Children's Hospital, Orlando

35128

University of Padova School of Medicine, Padua

37075

Children's University Hospital, Göttingen, Göttingen

37232

Vanderbilt Children's Hospital, Nashville

43205

Nationwide Children's Hospital, Columbus

45122

University Hospital of Essen, Essen

60614

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

66160

University of Kansas Medical Center, Kansas City

79110

University Medical Center Freiburg, Freiburg im Breisgau

84132

University of Utah Medical Center, Salt Lake City

87131

University of New Mexico Health Science Center, Albuquerque

90095

University of California Los Angeles (UCLA) Medical Center, Los Angeles

95817

University of California Davis Medical Center, Sacramento

98125

University of Messina AOU Policlinico Gaetano Martino, Messina

02115

Boston Children's Hospital, Boston

T3B 6A8

Alberta Children's Hospital, Calgary

N6A 4G5

Children's Hospital London Health Sciences Centre, London

K1H 8L1

Children's Hospital of Eastern Ontario (CHEO), Ottawa

01307

Children's Hospital, Technical University Dresden, Dresden

LS2 9NS

The General Infirmary at Leeds, Leeds

G3 8SJ

Greater Glasgow and Clyde NHS Yorkhill Hospital, Glasgow

B9 5SS

Heart of England NHS Foundation Trust Birmingham Heartland's Hospital, Birmingham

L12 2AP

Alder Hey Children's Hospital NHS Trust, Liverpool

WC1N 3JH

Great Ormond Street Hospital for Children NHS Trust, London

M13 9WL

Royal Manchester Children's Hospital, Manchester

NE1 3BZ

Institute of Human Genetics, International Centre for Life, Newcastle upon Tyne

All Listed Sponsors
collaborator

Newcastle University

OTHER

collaborator

University Medical Center Freiburg

OTHER

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Rochester

OTHER

NCT01603407 - Finding the Optimum Regimen for Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter